Subcutaneous Daratumumab Plus VRd Significantly Improved PFS, Increased Depth of Response in Patients With Newly Diagnosed Multiple Myeloma

Source: Pharmacy Times articles

These data support the combination of daratumumab plus VRd followed by daratumumab and lenalidomide maintenance as a new standard of care for transplant-eligible patients.
Read More